Our Twitter Accounts

Follow us on Twitter

facebook

https://www.facebook.com/PYCKStocks

twitter

https://twitter.com/#!/HogsNstocks

https://twitter.com/#!/LibbieStocks

https://twitter.com/#!/PaloStocks

https://twitter.com/PYCK_Consultant

https://twitter.com/#!/Nyx_TrAdah

https://twitter.com/#!/StockPycks

https://twitter.com/#!/PYCKGlobal

https://twitter.com/PYCKSocialMedia

https://twitter.com/#!/StocksChristian

https://twitter.com/CptJackPennies

Curis, Inc.~ Nasdaq Bio~ CRIS due diligence

Curis, Inc.~ Nasdaq Bio~ CRIS due diligence 

CRIS Company Overview & Description 

Curis, Inc is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at http://www.curis.com 

CRIS Corporate Fact Sheet: http://www.curis.com/Corp_Fact_Sheet_2011.pdf 

CRIS Corporate Overview Presentation: http://www.curis.com/Corporate_Overview.pdf 

CRIS Key Company Management 

Daniel R. Passeri
President and Chief Executive Officer 
Mr. Passeri has served as our President and Chief Executive Officer and as a director since September 2001. From November 2000 to September 2001, Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of the Company. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri is a graduate of the National Law Center at George Washington University, with a J.D., of the Imperial College of Science, Technology and Medicine at the University of London, with an M.Sc. in biotechnology, and of Northeastern University, with a B.S. in biology. 

Maurizio Voi, M.D.
Chief Medical and Chief Development Officer 
Dr. Voi has served as our Chief Medical and Chief Development Officer since November 2011. From October 2009 until November 2011, Dr. Voi was employed by Pfizer as Vice President of Clinical Development and Medical Affairs at the Oncology Business Unit of Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval in 2011. Prior to joining Pfizer, Dr. Voi served from 1998 to 2009 in several key positions at Bristol-Myers Squibb Company, most recently as the Executive Director, Global Clinical Development and Medical Affairs, Oncology, where he was instrumental in the development and regulatory submission and approval of Sprycel® in chronic myelogenous leukemia as well as in supplemental BLA’s of Erbitux® in colorectal, non-small cell lung and head and neck cancers. From 1987-1999, he served in several roles at Eli Lilly and Company, where he was involved in preparing the registration dossier for a regulatory approval filing in non-small cell lung cancer of Gemzar® in Europe as well as ultimately assuming responsibility for Gemzar® worldwide development and commercialization. 

Dr. Voi received his medical degree from the University of Padua, School of Medicine Italy and practiced medicine at the General Hospital, Dolo in Venice, Italy. 

Michael P. Gray
Chief Operating and Chief Financial Officer 
Mr. Gray has served as our Chief Operating Officer and Chief Financial Officer since December 2006. From December 2003 until December 2006, Mr. Gray served as our Vice President of Finance and Chief Financial Officer and served as our Senior Director of Finance and Controller from August 2000 until December 2003. Mr. Gray held financial positions including Controller and de Facto Chief Financial Officer at Reprogenesis, a predecessor biotechnology company, from January 1998 until July 2000. Mr. Gray previously served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a certified public accountant, holds an M.B.A. from the F.W. Olin Graduate School of Business at Babson College, and has a B.S. in accounting from Bryant College. 

Changgeng Qian, Ph.D., M.D.
Senior Vice President, Discovery and Preclinical Development 
Dr. Qian joined Curis in 2001. He has over 30 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. Prior to Curis, he played a key role in the discovery of several anti-inflammation, anticancer and CNS drug candidates at CytoMed Inc., LeukoSite Inc., and Millennium Pharmaceuticals, Inc. He is an inventor on more than 10 issued U.S. patents and over 25 published PCT patents and has authored approximately 30 scientific publications. Dr. Qian earned a Ph.D. in Pharmacology and an M.D. from the Hunan Medical University and has served as a professor of the University since 1992. 

Mark Noel
Vice President, Technology Management and Intellectual Property 
Mr. Noel has served as our Vice President, Technology Management and Intellectual Property since September 2008. From March 2001 until September 2008, Mr. Noel served as our Vice President, Technology Management and Business Development. From March 2000 to February 2001, Mr. Noel was employed by GeneLogic, as Vice President of Customer Relations. From January 1998 to February 2000, Mr. Noel was employed by GeneLogic as Senior Director of Program Management. From December 1993 to January 1998, Mr. Noel was employed by the National Cancer Institute’s Office of Technology Development (now the Technology Transfer Branch of the NCI Office of Technology and Industrial Relations), where from July 1997 to January 1998, he served as Acting Deputy Director. From February 1989 to November 1993, Mr. Noel worked as a patent agent at Gist Brocades NV, a supplier of ingredients to the pharmaceutical and food sectors. Mr. Noel holds a B.S. from the University of Maryland. 

CRIS Contact Info 

Curis Inc. Corporate Headquarters 
4 Maguire Road 
Lexington, MA 02421 
Tel: [617] 503-6500 
Fax: [617] 503-6501 

Website: http://www.curis.com 

Email Alert Subscription: http://investors.curis.com/alerts.cfm? 

Contact IR 
Curis, Inc. 
4 Maguire Road 
Lexington, MA 02421 
Phone: 617-503-6500 
E-mail: info@curis.com 

CRIS Recent Developments 

SEC Filings 
http://finance.yahoo.com/q/sec?s=CRIS+SEC+Filings 
Competitors 
http://finance.yahoo.com/q/co?s=CRIS+Competitors 
Industry 
http://finance.yahoo.com/q/in?s=CRIS+Industry 
Headlines 
http://finance.yahoo.com/q/h?s=CRIS+Headlines 

Current Corporate Collaborators 
Collaborator Program Disease 
Genentech (vismodegib) Hedgehog Pathway Inhibitor Cancer 
Debiopharm SA (Debio 0932) Debio 0932 (Hsp90 inhibitor; formerly CUDC-305) Cancer 
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs. 

The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute. 
http://www.curis.com/collaborations_detail.php?collaborationid=1 

Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing. 
http://www.curis.com/collaborations_detail.php?collaborationid=7 

CRIS Products & Services 

Over the past several years, targeted cancer drugs have been considered among the most promising cancer treatments for obtaining a therapeutic effect with less toxicity when compared with traditional chemotherapy, which, in addition to attacking cancerous cells, also tends to attack a broad range of healthy cells. A large body of published data shows cancers to have multiple, intersecting signaling pathways that support survival, growth, and invasion. Targeting only one or two of these pathways with single-targeted agents has generally only led to modest improvements to existing standards-of-care and most cancer patients with solid tumors do not respond in a clinically meaningful manner. Targeting the correct combination of critical signaling pathways within the network of cancer cell signaling pathways could provide a major improvement in outcomes for cancer patients and is an area of intense research and development. 

Curis is utilizing medicinal chemistry and biological expertise to develop a series of proprietary targeted cancer drug programs. These programs focus on the development of single-agent drug candidates targeting one or more molecular components within the signaling pathways associated with certain cancers. These programs are primarily focused on developing a number of proprietary, small molecule, single-agent, multi-targeted inhibitor drug compounds. Each proprietary compound is being designed to inhibit biologically- or clinically-validated cancer targets, including, among others, EGFR, Her2, Bcr-Abl tyrosine kinase and phosphatidylinositol-3-kinase (PI3k), in combination with inhibition of HDAC, which is a validated non-kinase cancer target. Curis is also seeking to use this platform to develop proprietary, differentiated, single-agent, single-target drug candidates for cancer indications. 

HDAC inhibition is a core component in each of Curis’ multi-targeted inhibitors. Curis believes that HDAC is a promising non-kinase target for cancer therapy, particularly when combined with simultaneous inhibition of certain other targets. There is substantial preclinical evidence of synergistic induction of cancer cell death when HDAC inhibitors are combined with a diverse range of other targeted therapies or standard chemotherapeutic agents, demonstrating that HDAC inhibition may be more broadly effective in the treatment of cancer when integrated with other inhibitory activities. 

Currently, there are two Food and Drug Administration, or FDA, approved HDAC inhibitors and several other HDAC-targeted drug candidates in clinical trials for cancer.
In furtherance of the development of Curis’ targeted cancer programs, the Company outsources certain medicinal chemistry and other preclinical functions with contract research organizations in China. Curis has developed these relationships with Chinese providers to support its U.S. operations and Curis is currently engaging approximately 25 chemists in China. Curis’ drug discovery efforts utilize significant medicinal chemistry resources. The Company’s management believes that these relationships have been important to Curis’ efforts to create a broad portfolio of proprietary cancer drugs by generating several classes of compounds for further development in a cost-effective manner. 

Curis filed a number of patents including a broad omnibus patent application that covers the drug design concept that is the basis for the multi-targeted cancer programs, as well as numerous species filings relating to specific classes of compounds which Curis believes will constitute novel compositions from a patentability standpoint. Curis expects that it will continue to file additional patent applications covering new compositions in the future. 

CUDC-101, Curis’ first drug candidate from our targeted cancer programs, is being designed as a multi-target inhibitor of HDAC, EGFR and Her2 and is currently the subject of a phase Ib expansion clinical trial as well as a Phase I trial in head and neck cancer in combination with radiation and cisplatin. Curis is also developing CUDC-907, a PI3K/HDAC inhibitor and expects that it will submit an IND for this molecule in early 2012. In August, 2009 Curis licensed its first single-agent, single-target inhibitor drug candidate, CUDC-305 (now Debio 0932), an Hsp90 inhibitor to Debiopharm. Curis researchers are continuing to investigate other classes of compounds in an effort to advance additional compounds into clinical development. 

Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs. 

The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech submitted a New Drug Application (NDA) to the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute. 

Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase Ib clinical testing. 

Curis also recently selected orally-available PI3K/HDAC inhibitor CUDC-907 as a development candidate and expects to begin Phase I clinical testing with this molecule in early 2012. 
Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of EGFR, Her2 and HDAC, in the first half of 2010. The Company also initiated in August 2010 a Phase Ib expansion trial of this molecule in patients with breast, gastric, head and neck, liver and non-small cell lung cancers and in August 2011 initiated a Phase I clinical trial in HPV- locally advanced head and neck cancer in combination with standard-of-care treatment (cisplatin and radiation). 

In addition, Curis has several programs that are in various stages of preclinical drug development. Because of the early stages of development of these programs, its ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain. 

Financial Reporting/Disclosure & Security Details 
Shareholders tools: http://investors.curis.com/ 

CRIS follows under these quidelines on the Nasdaq market tier. 

Investigate more @ http://www.otcmarkets.com/stock/CRIS/quote for more due diligence. 

Share Structure 
Market Cap. (Mil) $336.19 
Shares Out (Mil)76.58 
Float (Mil)56.84 
Share Related information provided by MorningStar, Inc. 
Data as of Jan 9, 2012. 
Mil=Millions 
watch updates here: http://investors.curis.com/financials.cfm 

Par Value: .01 

Shareholders 
Shareholders of Record: 76 
Transfer Agent(s) 
BNY Mellon Shareowner Services 
P.O. Box 358015 
85 Challenger Road 
Pittsburgh, PA 15252-8015 
Phone: 877.810.2248 
TA Corporate Website: http://www.bnymellon.com/shareowner/isd 

Financial Reporting/Disclosure 
Reporting Status: U.S. Registered & Reporting: SEC Filer 
OTC Disclosure last 10Q reported Oct 31, 2011 period ending Sept 30, 2011 
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8212490 
OTC Disclosure last 10K reported Mar 8, 2011 period ending Dec 31, 2011 
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7783210 
CIK: 0001108205 
Fiscal Year End: 12/31 
OTC Market Tier: Nasdaq 

Profile Data 
SIC - Industry Classification: CURIS, INC. - SIC # 2836 
Sector: HealthCare 
Industry: Biotechnology
Incorporated In: DE, USA 
Year of Inc: 
Employees: 32 

Before You Invest - Investigate! Always do your own due diligence 
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing. 

Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy. 

Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CRIS website 

(CRIS website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.) 

Images by StocksDiva

StocksDiva has not been compensated for these images in this post

Due Diligence by PYCK Global Marketing

http://pyckglobal.blogspot.com/

PYCK Global Marketing has not been compensated for this Due Diligence post

Disclaimer

ViroPharma Incorporated ~ Nasdaq Bio~ VPHM due diligence

 

ViroPharma Incorporated ~ Nasdaq Bio~ VPHM due diligence

VPHM Company Overview & Description 

Quote:

---

Your Dream is our Vision: Life-saving medicines for life-threatening diseases

---

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). 


VPHM goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx the prescribing information for other countries can be found at http://www.viropharma.com. 


ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business. 


ViroPharma Europe is ViroPharma's wholly-owned European subsidiary, which commenced in 2007 to leverage in Europe the company's expertise in the development and commercialization of biotechnology products, and in business development. ViroPharma seeks to acquire opportunities in areas of strategic interest to the company; Our strategy is to target serious diseases by building franchises within narrowly focused prescribing groups, with an initial niche focus on C1 esterase inhibitor deficiency and seizures in children and adolescents. Our interest could expand into other areas if they are compatible with our general business plan (i.e. niche opportunities, supportable by specialty marketing). 


- Belgium
- France
- Germany
- Italy
- Spain
- Switzerland
- United Kingdom 

 

VPHM Key Company Management 


Colin Broom
Vice President, Chief Scientific Officer 
Colin Broom, M.D. has served as Vice President, Chief Scientific Officer of ViroPharma since May 2004. From 2000 until 2003 Dr. Broom served as vice president of clinical development and medical affairs, Europe, for Amgen. From 1998 to 1999, Dr. Broom served as senior vice president of global clinical development for Hoechst Marion Roussel, now Aventis. From 1984 through 1998, Dr. Broom was with Glaxo and then SmithKline Beecham, where he held positions of increasing seniority in clinical pharmacology in Europe before moving to the US to head global oncology and subsequently becoming Vice President of CNS/GI. Dr. Broom holds a Bachelor of Science degree in pharmacology from University College in London, and a Bachelor of Medicine and Bachelor of Surgery degree from St. George's Hospital Medical School. Dr. Broom is a Member of the Royal College of Physicians and a Fellow of the Faculty of Pharmaceutical Medicine of the UK Colleges of Physicians. 


Thomas F. Doyle
Vice President, Strategic Initiatives 
Thomas F. Doyle is ViroPharma’s Vice President, Strategic Initiatives as of January 2008; he previously served as Vice President, General Counsel of ViroPharma since November 1997, as Secretary since February 1997 and as Executive Director, Counsel since joining ViroPharma in November 1996. From 1990 until 1996, Mr. Doyle was a corporate attorney with the law firm of Pepper, Hamilton LLP. Mr. Doyle received his J.D. from Temple University School of Law. Prior to attending Temple University, Mr. Doyle was a Certified Public Accountant. Mr. Doyle received his B.S. in Accounting from Mt. St. Mary's College. 


Robert C. Fletcher
Vice President, Business Development and Project Management 
Robert C. Fletcher is our Vice President, Business Development and Project Management. Mr. Fletcher joined ViroPharma in 2001 as a project leader, and has since held roles of increasing seniority during his tenure in the areas of business development and project management. Prior to joining ViroPharma, Mr. Fletcher held multiple roles of escalating responsibility at SmithKline Beecham Pharmaceuticals/GlaxoSmithKline, Becton-Dickinson and Company, Zynaxis Inc./Intracell Corporation, and Centocor Corporation. He holds both a master of science degree and a bachelor of arts degree in biology from Wake Forest University. 


Vincent J. Milano
President, Chief Executive Officer and Chairman of the Board of Directors 
Vincent Milano is ViroPharma’s President and Chief Executive Officer, and Chairman of the Board of Directors as of March 2008. He joined the company in 1996 and served as vice president, chief financial officer, and treasurer from 1997 to 2006. In 2006, he assumed the role of vice president, chief financial officer and chief operating officer. Mr. Milano has been instrumental in building ViroPharma, including leading efforts in raising nearly $900 million in capital and the acquisition of Vancocin(R) from Eli Lilly and Company. He has played a critical role in all business development and investor relations activities of the company, and has contributed significantly to establishing the strategic direction of the company. Prior to joining ViroPharma, he was with KPMG LLP, independent certified public accountants, where he served as senior manager. Mr. Milano received his bachelor of science degree in accounting from Rider College. 

 

VPHM Contact Info 


ViroPharma Incorporated 
730 Stockton Drive 
Exton, PA 19341 
Voice: 610-458-7300 
Toll-free Voice: 1-888-651-0201 
Facsimile: 610-458-7380 
For assistance in acquiring Cinryze™ (C1 Esterase Inhibitor [human]), please call the CINRYZESolutions Support Program at 1-877-945-1000 


Website: http://www.viropharma.com 


European Headquarters 
ViroPharma SPRL - BVBA 
rue Montoyer 47 
1000 Brussels 
Belgium 
Tel: +32 (0)2 747 0971 
Fax: +32 (0)2 706 2421 

 

VPHM Recent Developments 


http://finance.yahoo.com/q/h?s=VPHM+Headlines 

 

VPHM Products and Pipeline 

ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs. 


Our product CINRYZE® (C1 Esterase Inhibitor [Human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE), a rare and potentially life threatening genetic inflammatory disorder. Our product VANCOCIN® is the only antibiotic approved to treat two significant bacterial infections of the lower digestive tract. The product is administered orally and is indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by Clostridium difficile 


The company is also assessing non-toxigenic C. difficile (VP20621) with the goals of preventing the recurrence of disease following effective therapy for acute C. difficile infection (CDI) and preventing CDI in patients who are susceptible to colonization with toxigenic strains due to prior use of antibiotics. 

 

Financial Reporting/Disclosure & Security Details 


VPHM follows under these quidelines on the Nasdaq market tier. 


Investigate more @ http://www.otcmarkets.com/stock/VPHM/quote for more due diligence. 


Share Structure 
Market Cap a/o 1/2/11 1.93B 
Number of shares outstanding of the issuer’s Common Stock, par value $.002 per share, as of October 18, 2011: 70,542,868 shares. 
Common stock, par value $0.002 per share. 175,000,000 shares authorized; issued and outstanding 70,542,125 shares at September 30, 2011 and 78,141,491 shares at December 31, 2010 
(per last 10Q, link posted below) 
Float listed per Yahoo Fiance: 65.46M 


Shareholders 
Shareholders of Record:  213
Transfer Agent(s) 
Broadridge Financial Solutions, Inc. 
44 W. Lancaster Avenue 
Ardmore, PA, 19003 
610-649-7300 


Financial Reporting/Disclosure 
Reporting Status: U.S. Registered & Reporting: SEC Filer 
CIK: 0000946840 
Fiscal Year End: 12/31
OTC Market Tier: M - Nasdaq 


Profile Data 
SIC - Industry Classification: # 2834 
Business Status Development Stage Company: Health Care / Biotechnology 
Incorporated In: DE, USA 
Year of Inc: 1994
Employees: 232 


Security Notes 
New Issue=11-96 2,250,000 shs at $7 by Cowen & Co. et al. 


OTC Disclosure last 10Q reported Oct 27, 2011 period ending Sept 30, 2011 
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8207500 

 

Before You Invest - Investigate! Always do your own due diligence 
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing. 


Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy. 


Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, VPHM website 

Images by StocksDiva

StocksDiva has not been compensated for these images in this post

Due Diligence by PYCK Global Marketing

http://pyckglobal.blogspot.com/

PYCK Global Marketing has not been compensated for this Due Diligence post

Disclaimer

2012 Disclaimer

2012

PYCK Global Marketing or PYCK Stocks has not been compensated for VPHM due diligence and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for CRIS due diligence and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for QGEN due diligence and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for MGM due diligence and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for SNET tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for WYN due diligence and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for SCFR due diligence and tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for LGMH due diligence and tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $200 for UPZS tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $200 for BEES tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for ZERO tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $300 for ARNH tweeting  and profile and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for GTRL tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for SRPX tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $200 for BCCI tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for HRID tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $150 for HHII tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for SEFE tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $200 for HNSS tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $500 for LGMH tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $150 for DIGX tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks will be compensated by a third party $250 a week for LGMH investor awareness/relations, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for FVRG tweeting and does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $125 for NOUV tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $150 for SMAA tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $100 for ACLP tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks  has been compensated by a third party $100 for WBSI tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for AXLX tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for EWRL tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks  has been compensated by a third party $200 for FVRG tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks  has been compensated by a third party $300 for GNUS tweeting, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for MYRY tweeting and profile, does not hold a position is this stock.

PYCK Global Marketing or PYCK Stocks has not been compensated for LDSI tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for NANI tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for CFGX tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for INAR tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for TEWI tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for ICOR tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for ADHC tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for AERO tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for DIGX tweeting and profile.

PYCK Global Marketing or PYCK Stocks has not been compensated for EMLL tweeting and profile.

PYCK Global Marketing or PYCK Stocks has been compensated by a third party $300 for GNGR tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for FBCD tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated by a third party  for SRNG tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated by a third party  for GFMH tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for BRWC tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for GDAR tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for SMAA tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for GSTV tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for LFAP tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for VGPR tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for NILA tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for SUNB tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for GDTK profile

PYCK Global Marketing or PYCK Stocks has not been compensated for STLK tweeting and profile

PYCK Global Marketing or PYCK Stocks has compensated $100 for WTCG tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for FITX tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated for EARH tweeting and profile

2013
PYCK Global Marketing or PYCK Stocks has been compensated $100 for NWTR tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for TUCN tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for DRHC tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $50  for GGCO tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for CCRY tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for CDIF tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for GDAR tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for ADCF tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for VTMB tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for DVAX tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $250  for LGMH tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $150  for PMEA tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $150  for INDG tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $125  for TRLR tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for OTOW tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for FITX tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for REDG tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for AUCI tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for TTIN tweeting and profile

PYCK Global Marketing or PYCK Stocks has not been compensated  for PLPE tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $250  for VSTA tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for NANI tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for SMAA tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $250  for TRLR tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for DNAD tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for EDXC tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $100  for VIZS tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for GLBH tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for WDAS tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for ETEK tweeting and profile

PYCK Global Marketing or PYCK Stocks has been compensated $150  for BFLX tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for WAFR tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for RSII tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for BYSD tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for GRLT tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for NANI tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated $150  for PGVI tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for IALS tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for DPHS tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for VIZS tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for SFPI tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for SNET tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for ARTH tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for EXHI tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for USRC tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  form TRLR tweeting

PYCK Global Marketing or PYCK Stocks expects to be compensated  for BLUU tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for MLGT tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for FRTN profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for LVGI tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for GLBH tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for BFLX tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for MXAM tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for PIEX tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for BLDW tweeting and profile

PYCK Global Marketing or PYCK Stocks expects to be compensated  for AXLX tweeting and profile

2013
PYCK Social Media Consultants expects to be compensated for STCC tweeting and profile

PYCK Social Media Consultants expects to be compensated for IOGA tweeting and profile

PYCK Social Media Consultants expects to be compensated for ERBB tweeting and profile

PYCK Social Media Consultants expects to be compensated for LFAP tweeting and profile

PYCK Social Media Consultants expects to be compensated for AMPG tweeting and profile

PYCK Social Media Consultants expects to be compensated for NVLX tweeting and profile

PYCK Social Media Consultants expects to be compensated for MLGT tweeting and profile

PYCK Social Media Consultants expects to be compensated for BLUUD tweeting and profile

PYCK Social Media Consultants expects to be compensated for REFG tweeting and profile

PYCK Social Media Consultants expects to be compensated for GRNE tweeting and profile

PYCK Social Media Consultants expects to be compensated for GYST tweeting and profile

PYCK Social Media Consultants expects to be compensated for AXXE tweeting and profile

PYCK Social Media Consultants expects to be compensated for FNRC tweeting and profile

PYCK Social Media Consultants expects to be compensated for USEI tweeting and profile

PYCK Social Media Consultants expects to be compensated for ETEK tweeting and profile

PYCK Social Media Consultants expects to be compensated for PRDL tweeting and profile

PYCK Social Media Consultants expects to be compensated for IALS tweeting and profile

PYCK Social Media Consultants expects to be compensated for AXCG tweeting and profile

PYCK Social Media Consultants expects to be compensated for HNSS tweeting and profile

PYCK Social Media Consultants expects to be compensated for ERNI tweeting and profile

PYCK Social Media Consultants expects to be compensated for BLUU tweeting and profile

PYCK Social Media Consultants expects to be compensated for DKAM tweeting and profile

PYCK Social Media Consultants expects to be compensated for EMJI tweeting and profile

PYCK Social Media Consultants expects to be compensated for IBRC tweeting and profile

PYCK Social Media Consultants expects to be compensated for RSII tweeting and profile

PYCK Social Media Consultants expects to be compensated for MWAR tweeting and profile

PYCK Social Media Consultants expects to be compensated for MYEC tweeting and profile

PYCK Social Media Consultants expects to be compensated for NVGC tweeting and profile

PYCK Social Media Consultants expects to be compensated for DKAM tweeting and profile

PYCK Social Media Consultants expects to be compensated for EXHI tweeting and profile

PYCK Social Media Consultants expects to be compensated for WSHE tweeting and profile